statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HC Wainwright reissued their buy rating on shares of Aptose Biosciences (NASDAQ:APTO - Free Report) (TSE:APS) in a research note published on Wednesday morning, Benzinga reports. HC Wainwright...

Aptose Biosciences (NASDAQ:APTO) Stock Rating Reaffirmed by HC Wainwright

Aptose Biosciences (NASDAQ:APTO - Get Free Report) (TSE:APS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating in a research note issued to investors on...

Aptose Biosciences (NASDAQ:APTO) Rating Increased to Hold at StockNews.com

Aptose Biosciences Inc. (NASDAQ:APTO  Get Free Report) (TSE:APS) was the recipient of a large decline in short interest in March. As of March 15th, there was short interest totalling 50,200...

Short Interest in Aptose Biosciences Inc. (NASDAQ:APTO) Decreases By 28.7%

Shares of Aptose Biosciences Inc. (NASDAQ:APTO  Get Free Report) (TSE:APS) have earned an average rating of Buy from the five research firms that are currently covering the...

Aptose Biosciences Inc. (NASDAQ:APTO) Receives $36.50 Consensus Price Target from Brokerages

Q4 2023 Aptose Biosciences Inc Earnings Call Transcript

Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AMLTuspetinib Continues Broad Activity Across Mutations with Excellent Safety ProfileLuxeptinib G3 Formulation Achieves Desired...

Aptose Reports Results for the Fourth Quarter and Full Year 2023

Aptose Biosciences Q4 2023 Earnings Preview...

Aptose Biosciences Q4 2023 Earnings Preview

Aptose Biosciences's Earnings: A Preview

Aptose Biosciences Inc. (NASDAQ:APTO  Get Free Report) (TSE:APS) has earned a consensus rating of Buy from the six brokerages that are presently covering the stock, MarketBeat...

Aptose Biosciences Inc. (NASDAQ:APTO) Receives Average Rating of "Buy" from Brokerages

SAN DIEGO and TORONTO, March 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral...

Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024

Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.

Volume	56,226.00
52-Wk High	$8.70
52-Wk Low	$1.20

APTO Aptose Biosciences Inc

About

Feed

News

Sentiment

Earnings

Fundamentals